106 related articles for article (PubMed ID: 23828865)
1. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.
Gild ML; Landa I; Ryder M; Ghossein RA; Knauf JA; Fagin JA
Endocr Relat Cancer; 2013 Oct; 20(5):659-67. PubMed ID: 23828865
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Activity of RXDX-105 in Multiple Cancer Types with
Li GG; Somwar R; Joseph J; Smith RS; Hayashi T; Martin L; Franovic A; Schairer A; Martin E; Riely GJ; Harris J; Yan S; Wei G; Oliver JW; Patel R; Multani P; Ladanyi M; Drilon A
Clin Cancer Res; 2017 Jun; 23(12):2981-2990. PubMed ID: 28011461
[No Abstract] [Full Text] [Related]
3. Directly imaging the localisation and photosensitization properties of the pan-mTOR inhibitor, AZD2014, in living cancer cells.
Ahmed AR; Candeo A; D'Abrantes S; Needham SR; Yadav RB; Botchway SW; Parker AW
J Photochem Photobiol B; 2020 Dec; 213():112055. PubMed ID: 33142217
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors.
Acharya B; Saha D; Garcia Garcia N; Armstrong D; Jabali B; Hanafi M; Frett B; Ryan KR
Bioorg Med Chem; 2024 May; 106():117749. PubMed ID: 38744018
[TBL] [Abstract][Full Text] [Related]
5. Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.
Steen EA; Basilaia M; Kim W; Getz T; Gustafson JL; Zage PE
Biochem Pharmacol; 2023 Oct; 216():115751. PubMed ID: 37595672
[TBL] [Abstract][Full Text] [Related]
6. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
Frett B; Carlomagno F; Moccia ML; Brescia A; Federico G; De Falco V; Admire B; Chen Z; Qi W; Santoro M; Li HY
Angew Chem Int Ed Engl; 2015 Jul; 54(30):8717-21. PubMed ID: 26126987
[TBL] [Abstract][Full Text] [Related]
7. Mtor inhibition by INK128 extends functions of the ovary reconstituted from germline stem cells in aging and premature aging mice.
Heng D; Sheng X; Tian C; Li J; Liu L; Gou M; Liu L
Aging Cell; 2021 Feb; 20(2):e13304. PubMed ID: 33448083
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of two novel oncogenic mTOR mutations.
Murugan AK; Liu R; Xing M
Oncogene; 2019 Jun; 38(26):5211-5226. PubMed ID: 30918329
[TBL] [Abstract][Full Text] [Related]
9. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.
Frett B; Moccia M; Carlomagno F; Santoro M; Li HY
Eur J Med Chem; 2014 Oct; 86():714-23. PubMed ID: 25232968
[TBL] [Abstract][Full Text] [Related]
10. Advances in Targeting RET-Dependent Cancers.
Subbiah V; Cote GJ
Cancer Discov; 2020 Apr; 10(4):498-505. PubMed ID: 32094155
[No Abstract] [Full Text] [Related]
11. A Caged Ret Kinase Inhibitor and its Effect on Motoneuron Development in Zebrafish Embryos.
Bliman D; Nilsson JR; Kettunen P; Andréasson J; Grøtli M
Sci Rep; 2015 Aug; 5():13109. PubMed ID: 26300345
[TBL] [Abstract][Full Text] [Related]
12. Absence of somatic mutations of the mTOR gene in differentiated thyroid cancer.
Murugan AK; Humudh EA; Qasem E; Al-Hindi H; Almohanna M; Hassan ZK; Alzahrani AS
Meta Gene; 2015 Dec; 6():69-71. PubMed ID: 26504747
[TBL] [Abstract][Full Text] [Related]
13. Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I; Odintsov I; Ishida K; Lui AJW; Kato M; Suzuki T; Zhang T; Wakayama K; Kurth RI; Cheng R; Fujita H; Delasos L; Vojnic M; Khodos I; Yamada Y; Ishizawa K; Mattar MS; Funabashi K; Chang Q; Ohkubo S; Yano W; Terada R; Giuliano C; Lu YC; Bonifacio A; Kunte S; Davare MA; Cheng EH; de Stanchina E; Lovati E; Iwasawa Y; Ladanyi M; Somwar R
Nat Cancer; 2023 Sep; 4(9):1345-1361. PubMed ID: 37743366
[TBL] [Abstract][Full Text] [Related]
14. Correction to "Design and Synthesis of Novel Thieno[3,2-
La Monica G; Pizzolanti G; Baiamonte C; Bono A; Alamia F; Mingoia F; Lauria A; Martorana A
ACS Omega; 2023 Dec; 8(50):48582. PubMed ID: 38144131
[TBL] [Abstract][Full Text] [Related]
15. Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.
Rosen EY; Won HH; Zheng Y; Cocco E; Selcuklu D; Gong Y; Friedman ND; de Bruijn I; Sumer O; Bielski CM; Savin C; Bourque C; Falcon C; Clarke N; Jing X; Meng F; Zimel C; Shifman S; Kittane S; Wu F; Ladanyi M; Ebata K; Kherani J; Brandhuber BJ; Fagin J; Sherman EJ; Rekhtman N; Berger MF; Scaltriti M; Hyman DM; Taylor BS; Drilon A
Nat Commun; 2022 Apr; 13(1):1936. PubMed ID: 35383193
[No Abstract] [Full Text] [Related]
16. Integrated genomic characterization of papillary thyroid carcinoma.
Cancer Genome Atlas Research Network
Cell; 2014 Oct; 159(3):676-90. PubMed ID: 25417114
[TBL] [Abstract][Full Text] [Related]
17. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
Plenker D; Riedel M; Brägelmann J; Dammert MA; Chauhan R; Knowles PP; Lorenz C; Keul M; Bührmann M; Pagel O; Tischler V; Scheel AH; Schütte D; Song Y; Stark J; Mrugalla F; Alber Y; Richters A; Engel J; Leenders F; Heuckmann JM; Wolf J; Diebold J; Pall G; Peifer M; Aerts M; Gevaert K; Zahedi RP; Buettner R; Shokat KM; McDonald NQ; Kast SM; Gautschi O; Thomas RK; Sos ML
Sci Transl Med; 2017 Jun; 9(394):. PubMed ID: 28615362
[TBL] [Abstract][Full Text] [Related]
18. Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.
Richter S; Steenblock C; Fischer A; Lemm S; Ziegler CG; Bechmann N; Nölting S; Pietzsch J; Ullrich M
Theranostics; 2024; 14(1):17-32. PubMed ID: 38164150
[TBL] [Abstract][Full Text] [Related]
19. From Circulating Tumor Cells to Mirna: New Challenges in the Diagnosis and Prognosis of Medullary Thyroid Cancer.
Ricci C; Salvemini A; Dalmiglio C; Castagna MG; Cantara S
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568824
[TBL] [Abstract][Full Text] [Related]
20. The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.
Derwich A; Sykutera M; Bromińska B; Rubiś B; Ruchała M; Sawicka-Gutaj N
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
